Silverback Therapeutics in Supply Agreement for Libtayo With Regeneron

By Chris Wack

Silverback Therapeutics Inc. said it is in a clinical supply agreement with Regeneron Pharmaceuticals Inc. for Libtayo cemiplimab.

Silverback said the supply agreement supports the evaluation of Libtayo, a PD-1 inhibitor, in combination with SBT6050, a targeted immuno-oncology agent designed to direct a TLR8 agonist linker-payload to activate myeloid cells in tumors expressing moderate to high levels of HER2.

In the first quarter of 2021, Silverback began treatment in Part 3 of the Phase 1/1b study to evaluate the activity of SBT6050 in combination with a PD-1 inhibitor in dose escalation.

Under the terms of the agreement, Silverback will expand the ongoing Phase 1/1b trial to evaluate the combination of SBT6050 and Libtayo in tumor-specific dose expansion cohorts, initially in HER2-expressing non small cell lung cancer and gastric cancer.

Silverback shares were up 25% to $35.69 in premarket trading.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

July 07, 2021 08:14 ET (12:14 GMT)

Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Mar 2024 to Apr 2024